MediWound (MDWD) Reports Q3 Loss, Lags Revenue Estimates

Company Performance - MediWound reported a quarterly loss of $0.98 per share, significantly worse than the Zacks Consensus Estimate of a loss of$0.48, marking an earnings surprise of -104.17% [1] - The company's revenues for the quarter ended September 2024 were $4.36 million, missing the Zacks Consensus Estimate by 27.48$4.78 million a year ago [2] - Over the last four quarters, MediWound has surpassed consensus EPS estimates two times and topped consensus revenue estimates twice [2] Stock Movement and Outlook - MediWound shares have increased approximately 70.4% since the beginning of the year, outperforming the S&P 500's gain of 25.5% [3] - The future performance of the stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4][6] - The current consensus EPS estimate for the upcoming quarter is -$0.58 on revenues of$7.82 million, and for the current fiscal year, it is -$2.69 on revenues of$23.85 million [7] Industry Context - The Medical - Drugs industry, to which MediWound belongs, is currently ranked in the top 31% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]